BIAKŌS™ ANTIMICROBIAL WOUND GEL

BIAKŌS™ ANTIMICROBIAL WOUND GEL is a patented gel that synergistically disrupts extracellular polymeric substances to help eliminate biofilm microbes in the gel to aid in wound healing.

Buy Now Sales Brochure Product Insert

BIAKOS™ Antimicrobial Skin & Wound Cleanser

BIAKŌS™ ANTIMICROBIAL WOUND GEL Works Synergistically

The patented technology and ingredients in BIAKŌS™ ANTIMICROBIAL WOUND GEL work to:

Eliminate...

Planktonic, immature and mature biofilms.

Attack...

Gram-negative bacteria, Gram-positive bacteria, fungi and spores

Facilitate...

Normal wound-healing pH.

Support...

Autolytic debridement by softening necrotic tissue.

Create...

A safe environment conducive to wound healing.

Safely Disrupt Biofilm Microbes

BIAKŌS™ ANTIMICROBIAL WOUND GEL is intended for the management of:

• Diabetic foot ulcers • Leg ulcers • Pressure ulcers • First- and second-degree burns • Large surface areas • Surgical incisions

Ingredients in BIAKŌS™ ANTIMICROBIAL WOUND GEL Synergistic functions of the ingredients provide a powerful, yet gentle formulation while eliminating microbes in the gel.

*PHMB

Poloxamer 407

Ingredients in BIAKOS Antimicrobial Skin & Wound Cleanser

*Synergistic Ingedients

*Vicinal Diols

*EDTAs

Learn More about the Synergistic Ingredients

BIAKŌS™ Is Effective Against*

Gram-positive bacteria

Clostridium difficile

Enterococcus faecalis

Methicillin Resistant Staphylococcus aureus (MRSA)

Staphylococcus aureus

Staphylococcus epidermidis

Vancomycin Resistant Enterococcus faecalis (VREF)

Gram-negative bacteria

Acinetobacter baumannii

Carbapenum Resistant Escherichia coli (CRE)

Enterobacter cloacae

Escherichia coli

Klebsiella pneumoniae

Proteus mirabilis

Pseudomonas aeruginosa

Serratia marcescens

Fungi

Candida albicans

Candida auris

Trichosporin asahii

Trichophyton rubrum

Spores

Bacillus cereus

Clostridium difficile

*Kill rate testing in the gel; Data on file

Keep Up With the Latest Developments in Surgical and Wound Care Technology

Most Recent Press Releases

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2020 Results

March 31, 2021

Sanara MedTech Inc. Announces Closing of $31.6 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

February 18, 2021

Sanara MedTech Inc. Announces Pricing of Public Offering

February 12, 2021

All Press Releases

Get In Touch